Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 13

1.

Stromal androgen receptor roles in the development of normal prostate, benign prostate hyperplasia, and prostate cancer.

Wen S, Chang HC, Tian J, Shang Z, Niu Y, Chang C.

Am J Pathol. 2015 Feb;185(2):293-301. doi: 10.1016/j.ajpath.2014.10.012. Epub 2014 Nov 26. Review.

2.

Wnt signaling in castration-resistant prostate cancer: implications for therapy.

Yokoyama NN, Shao S, Hoang BH, Mercola D, Zi X.

Am J Clin Exp Urol. 2014 Apr 15;2(1):27-44.

3.

Intensity of stromal changes is associated with tumor relapse in clinically advanced prostate cancer after castration therapy.

Wu JP, Huang WB, Zhou H, Xu LW, Zhao JH, Zhu JG, Su JH, Sun HB.

Asian J Androl. 2014 Sep-Oct;16(5):710-4. doi: 10.4103/1008-682X.129131.

4.

VDR activity is differentially affected by Hic-5 in prostate cancer and stromal cells.

Solomon JD, Heitzer MD, Liu TT, Beumer JH, Parise RA, Normolle DP, Leach DA, Buchanan G, DeFranco DB.

Mol Cancer Res. 2014 Aug;12(8):1166-80. doi: 10.1158/1541-7786.MCR-13-0395. Epub 2014 May 13.

5.

Hic-5 is a transcription coregulator that acts before and/or after glucocorticoid receptor genome occupancy in a gene-selective manner.

Chodankar R, Wu DY, Schiller BJ, Yamamoto KR, Stallcup MR.

Proc Natl Acad Sci U S A. 2014 Mar 18;111(11):4007-12. doi: 10.1073/pnas.1400522111. Epub 2014 Mar 3.

6.

A reciprocal role of prostate cancer on stromal DNA damage.

Banerjee J, Mishra R, Li X, Jackson RS 2nd, Sharma A, Bhowmick NA.

Oncogene. 2014 Oct 9;33(41):4924-31. doi: 10.1038/onc.2013.431. Epub 2013 Oct 21.

7.

Establishment of a predictive genetic model for estimating chemotherapy sensitivity of colorectal cancer with synchronous liver metastasis.

Lu X, Pan J, Li S, Shen S, Chi P, Lin H, Huang Y, Xu Z, Huang S.

Cancer Biother Radiopharm. 2013 Sep;28(7):552-8. doi: 10.1089/cbr.2012.1431. Epub 2013 May 30.

8.

Diverse roles for the paxillin family of proteins in cancer.

Deakin NO, Pignatelli J, Turner CE.

Genes Cancer. 2012 May;3(5-6):362-70. doi: 10.1177/1947601912458582.

9.

Genistein cooperates with the histone deacetylase inhibitor vorinostat to induce cell death in prostate cancer cells.

Phillip CJ, Giardina CK, Bilir B, Cutler DJ, Lai YH, Kucuk O, Moreno CS.

BMC Cancer. 2012 Apr 11;12:145. doi: 10.1186/1471-2407-12-145.

10.

Loss of TGF-β responsiveness in prostate stromal cells alters chemokine levels and facilitates the development of mixed osteoblastic/osteolytic bone lesions.

Li X, Sterling JA, Fan KH, Vessella RL, Shyr Y, Hayward SW, Matrisian LM, Bhowmick NA.

Mol Cancer Res. 2012 Apr;10(4):494-503. doi: 10.1158/1541-7786.MCR-11-0506. Epub 2012 Jan 30.

11.

Hic-5 controls BMP4 responses in prostate cancer cells through interacting with Smads 1, 5 and 8.

Shola DT, Wang H, Wahdan-Alaswad R, Danielpour D.

Oncogene. 2012 May 10;31(19):2480-90. doi: 10.1038/onc.2011.422. Epub 2011 Sep 26.

12.

Transforming growth factor-β1-induced transcript 1 protein, a novel marker for smooth muscle contractile phenotype, is regulated by serum response factor/myocardin protein.

Wang X, Hu G, Betts C, Harmon EY, Keller RS, Van De Water L, Zhou J.

J Biol Chem. 2011 Dec 2;286(48):41589-99. doi: 10.1074/jbc.M111.250878. Epub 2011 Oct 8.

13.

Proline-rich tyrosine kinase 2 (Pyk2) promotes cell motility of hepatocellular carcinoma through induction of epithelial to mesenchymal transition.

Sun CK, Ng KT, Lim ZX, Cheng Q, Lo CM, Poon RT, Man K, Wong N, Fan ST.

PLoS One. 2011 Apr 20;6(4):e18878. doi: 10.1371/journal.pone.0018878.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk